Library
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
97 Results
Poster
A Phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
Author(s): Heymach et al.
Tumor type(s): Solid tumors
Compound/Target: HER2 TKI
KISIMA-01: A first-in-human trial of the heterologous prime-boost vaccine ATP128/VSV-GP128 with ezabenlimab (BI 754091) in patients with stage IV colorectal cancer
Author(s): Lenz et al.
Tumor type(s): Colorectal cancer
Compound/Target: KISIMA-01
Biomarker analyses from the Phase I clinical trial of the first-in-class SIRPa immune checkpoint inhibitor BI 765063 in patients with advanced solid tumors
Author(s): Champiat et al.
Tumor type(s): Solid tumors
Compound/Target: SIRPa
The beginning of the end for KRAS cancers
Author(s): Kraut et al.
Tumor type(s): Solid tumors
Compound/Target: KRAS
Meet-the-expert session
A first-in-human Phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6
Author(s): Falchook et al.
Tumor type(s): Solid tumors
Compound/Target: B7-H6/CD3
A Phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma
Author(s): Gounder et al.
Tumor type(s): Liposarcoma
Compound/Target: MDM2-p53
A Phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with immune checkpoint inhibitor(s) in patients with advanced solid tumors
Author(s): Yamamoto et al.
Tumor type(s): Liposarcoma
Compound/Target: MDM2-p53
Effect of performance status on treatment outcome with second-line nintedanib + docetaxel for patients with lung adenocarcinoma after first-line immune checkpoint inhibitor combination therapy
Author(s): Grohe et al.
Tumor type(s): Lung adenocarcinoma
Compound/Target: Triple angio-kinase inhibitor
A Phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumours
Author(s): Schoffski et al.
Tumor type(s): Solid tumours
Compound/Target: MDM2-p53
Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy
Author(s): Grohe et al.
Tumor type(s): Lung adenocarcinoma
Compound/Target: Triple angio-kinase inhibitor
A Phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma
Author(s): Gounder et al.
Tumor type(s): Solid tumors
Compound/Target: MDM2-p53
A Phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with immune checkpoint inhibitor(s) in patients with advanced solid tumors
Author(s): Tolcher et al.
Tumor type(s): Solid tumor
Compound/Target: MDM2-p53
A phase II/III, randomized, open-label, multicenter study of the MDM2–P53 antagonist BI 907828 vs doxorubicin in the first-line treatment of patients with dedifferentiated liposarcoma: Brightline-1
Author(s): Schöffski et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
Author(s): Yamamoto et al.
Tumor type(s): Solid tumors
Compound/Target: HER2 TKI
Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: data from two phase Ia/Ib dose-escalation/expansion trials
Author(s): Yamamoto et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
BI 907828: A highly potent MDM2–p53 antagonist suitable for intermittent dose schedules
Author(s): Gollner et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations
Author(s): Heymach et al.
Tumor type(s): Solid tumor
Compound/Target: HER2 TKI
A Phase IIa/IIb, open-label trial of the MDM2–p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma or other selected solid tumours. (Brightline-2)
Author(s): Macarulla et al.
Tumor type(s): Solid tumor
Compound/Target: MDM2-p53
A phase 0/Ia study of BI 907828 concentrations in brain tissue and a nonrandomized, open-label, dose escalation study of BI 907828 in combination with radiotherapy in patients with newly diagnosed glioblastoma (GBM)
Author(s): Sarkaria et al.
Tumor type(s): GBM
Compound/Target: MDM2-p53
A phase IIa/IIb, open-label trial of BI 907828, an MDM2–p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2
Author(s): Goyal et al.
Tumor type(s): Solid tumor
Compound/Target: MDM2-p53
Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, and MDM2a p53 antagonist
Author(s): Peltzer et al.
Tumor type(s): Solid tumor
Compound/Target: MDM2-p53
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data
Author(s): Heymach et al.
Tumor type(s): Solid tumor
Compound/Target: HER2 TKI
A Phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors: safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)
Author(s): LoRusso et al.
Tumor type(s): DDLPS
Compound/Target: MDM2-p53
An ongoing phase I trial of the DLL3/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive extrapulmonary neuroendocrine carcinomas
Author(s): Gambardella et al.
Tumor type(s): NET
Compound/Target: DLL3/CD3 TcE
Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: focus on neuroendocrine carcinomas
Author(s): Gambardella et al.
Tumor type(s): NET
Compound/Target: DLL3/CD3 TcE
Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs
Author(s): Mazières et al.
Tumor type(s): SCLC
Compound/Target: DLL3/CD3 TcE
A Phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
Author(s): Schöffski et al.
Tumor type(s): Solid tumors
Compound/Target: MDM2-p53
Beamion LUNG-1, an ongoing Phase Ia/Ib trial of the HER2 TKI, zongertinib (BI 1810631) in patients (pts) with advanced solid tumours with HER2 aberrations: latest data
Author(s): Ruiter et al.
Tumor type(s): Solid tumors
Compound/Target: HER2 TKI
Open-label, Phase I, dose escalation/expansion trial of the anti-SIRPα monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab
Author(s): Gutierrez et al.
Tumor type(s): Solid tumors
Compound/Target: SIRPα
Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Author(s): Calvo et al.
Tumor type(s): Solid tumors
Compound/Target: ezabenlimab
First-in-human, Phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation
Author(s): Heymach et al.
Tumor type(s): Solid tumors
Compound/Target: KRAS G12C
Assessing the replicative potential of the oncolytic virus VSV-GP in patient-derived tumor biopsies ex vivo
Author(s): Schoeps et al.
Tumor type(s): Solid tumors
Compound/Target: VSV-GP
Unmet needs in locally advanced (unresectable)or metastatic dedifferentiated liposarcoma and expectations for clinical trials: an international Delphi consensus study
Author(s): Schöffski et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
Efficacy and safety of brigimadlin (BI 907828), a MDM2–p53 antagonist, in patients with advanced biliary tract cancer: data from two Phase Ia/Ib dose-escalation/expansion trials
Author(s): Macarulla et al.
Tumor type(s): BTC
Compound/Target: MDM2-p53
Ezabenlimab (BI 754091) plus modified docetaxel, cisplatin, and 5-fluorouracil followed by chemoradiotherapy in patients with Stage III squamous cell carcinoma of the anus: early efficacy endpoint results from the Phase II INTERACT-ION study
Author(s): Kim et al.
Tumor type(s): SCAC
Compound/Target: Ezabenlimab
A Phase Ib, open-label, dose escalation trial of the delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive glioma
Author(s): van den Bent et al.
Tumor type(s): SCLC
Compound/Target: DLL3/CD3 TcE
Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer
Author(s): Lucas et al.
Tumor type(s): CRC
Compound/Target: anti-SIRPα
Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2–p53 antagonist brigimadlin and p53 function: a longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study
Author(s): Peltzel et al.
Tumor type(s): DDLPS
Compound/Target: MDM2-p53
Beamion LUNG-2: a phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) muta
Author(s): Johnson et al.
Tumor type(s): NSCLC
Compound/Target: HER2-TKI
A Phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain mutations: Beamion L
Author(s): Wu et al.
Tumor type(s): NSCLC
Compound/Target: HER2-TKI
Presentations
Development and Early Clinical Exploration of an MDM2-P53 Antagonist for Soft Tissue Sarcoma and Other Indications
Author(s): Schoffski et al.
Tumor type(s): Sarcoma
Targeting HER2 and KRAS to Deliver Breakthrough Therapies
Author(s): Smit et al.
Tumor type(s): Solid tumors
T-cell Engagers: Changing the Treatment Paradigm in Solid Tumors
Author(s): Reck et al.
Tumor type(s): Solid tumors
First-in-human dose-escalation trial of the delta-like ligand 3 (DLL3)/CD3 bispecific T-cell engager BI 764532 in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC)
Author(s): Wermke et al.
Tumor type(s): SCLC and NEC
Compound/Target: DLL3 TcE
An ongoing phase I trial of the DLL3/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive extrapulmonary neuroendocrine carcinomas
Author(s): Gambardella et al.
Tumor type(s): NET
Compound/Target: DLL3/CD3 TcE
Improving the Present: Selective HER2 TKI in NSCLC
Author(s): Cho et al.
Tumor type(s): NSCLC
Compound/Target: HER2 TKI
The Past: A Brief History of Personalized Therapy in Lung Cancer
Author(s): Loong et al.
Tumor type(s): Lung Cancer
Compound/Target:
Advancing Towards the Future: Targeting DLL3 in SCLC
Author(s): Goto et al.
Tumor type(s): SCLC
Compound/Target: DLL3/CD3 TcE
Phase I dose escalation trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients with DLL3+ tumors: focus on SCLC
Author(s): Wermke et al.
Tumor type(s): SCLC
Compound/Target: DLL3/CD3 TcE
Real-world characteristics and outcomes among patients with advanced non-small cell lung cancer and HER2 mutations
Author(s): Heymach et al.
Tumor type(s): NSCLC
Compound/Target: HER2 TKI
Beamion Lung 1, a Phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients with advanced solid tumors with HER2 aberrations
Author(s): Yamamoto et al.
Tumor type(s): Solid tumor
Compound/Target: HER2 TKI
Improving HER2 Targeting in NSCLC with Selective TKI
Author(s): Piotrowska et al.
Tumor type(s): NSCLC
Compound/Target: HER2 TKI
T-cell Engagers: Fighting Solid Tumors from Within
Author(s): Rudin et al.
Tumor type(s): SCLC
Compound/Target: DLL3/CD3 TcE
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients with solid tumors: safety and efficacy in patients with liposarcoma
Author(s): Schöffski et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors
Author(s): Heymach et al.
Tumor type(s): Solid tumors
Compound/Target: HER2 TKI
Phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin (BI 907828) in advanced solid tumours: overall safety, and efficacy in patients (pts) with well-differentiated liposarcoma (WDLPS)
Author(s): Reichardt et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
Beamion LUNG-1, a Phase Ia/b trial of zongertinib (BI 1810631) in patients with solid tumors: focus on patients with HER2 mutation-positive NSCLC
Author(s): Yoh et al.
Tumor type(s): NSCLC
Compound/Target: HER2 TKI
Phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients with DLL3-positive tumors: focus on Asian patients
Author(s): Kuboki et al.
Tumor type(s): SCLC
Compound/Target: DLL3/CD3 TcE
Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI) in patients (pts) with HER2 aberration-positive solid tumors: updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data
Author(s): Heymach et al.
Tumor type(s): Solid tumors
Compound/Target: HER2-TKI
Infographics
A Phase Ia/Ib, dose-escalation/expansion trial of BI 907828 in combination with immune checkpoint inhibitors(s) in patients with advanced solid tumors (NCT03964233)
Author(s): Yamamoto et al.
Tumor type(s): Solid tumors
Compound/Target: MDM2-p53
A Phase II/III, randomized, open-label, multicenter trial of BI 907828 compared to doxorubicin in the first-line treatment of patients with advanced dedifferentiated liposarcoma: Brightline-1
Author(s): Schoffski et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
Effect of best response to first-line treatment on outcomes with second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after first-line immunochemotherapy
Author(s): Grohe et al.
Tumor type(s): NSCLC
Compound/Target: Triple angio-kinase inhibitor
A Phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma
Author(s): Gounder et al.
Tumor type(s): Solid tumors and Sarcoma
Compound/Target: MDM2-p53
A Phase II/III, randomized, open-label, multicenter study of the MDM2–p53 antagonist BI 907828 vs doxorubicin in the first-line treatment of patients with dedifferentiated liposarcoma: Brightline-1
Author(s): Schöffski et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
A Phase Ia/b, dose-escalation and expansion study evaluating the MDM2–p53 antagonist BI 907828 in patients with solid tumours: safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)
Author(s): Schöffski et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data
Author(s): Heymach et al.
Tumor type(s): Solid tumor
Compound/Target: HER2 TKI
First-in-human dose-escalation trial of the delta-like ligand 3/CD3 bispecific T-cell engager BI 764532 in patients with DLL3-positive small-cell lung cancer and neuroendocrine carcinoma
Author(s): Wermke et al.
Tumor type(s): SCLC and NEC
Compound/Target: DLL3
A Phase IIa/IIb, open-label trial of the MDM2–p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma or other selected solid tumours. (Brightline-2)
Author(s): Macarulla et al.
Tumor type(s): Solid tumor
Compound/Target: MDM2-p53
Beamion LUNG-1, an ongoing Phase Ia/Ib trial of the HER2 TKI, zongertinib (BI 1810631) in patients (pts) with advanced solid tumours with HER2 aberrations: latest data
Author(s): Ruiter et al.
Tumor type(s): Solid tumors
Compound/Target: HER2 TKI
Phase I dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager) + ezabenlimab (anti-PD-1 antibody) in patients with small cell lung cancer and other neuroendocrine carcinomas (NECs) expressing DLL3
Author(s): Mazières et al.
Tumor type(s): SCLC
Compound/Target: DLL3/CD3 TcE
First-in-human, Phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation
Author(s): Heymach et al.
Tumor type(s): Solid tumors
Compound/Target: KRAS G12C
Longitudinal mutational analysis of TP53 in circulating tumor DNA in the plasma of patients with liposarcoma in a phase I study of brigimadlin (BI 907828), an MDM2-p53 antagonist
Author(s): Schöffski et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients with solid tumors: safety and efficacy in patients with liposarcoma
Author(s): Schöffski et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
Changes in computed tomography features induced by brigimadlin (BI 907828) in patients with liposarcoma: insights from phase 1 studies
Author(s): Schwartz et al.
Tumor type(s): Sarcoma
Compound/Target: MDM2-p53
A Phase Ib, open-label, dose escalation trial of the delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive glioma
Author(s): van den Bent et al.
Tumor type(s): SCLC
Compound/Target: DLL3/CD3 TcE
A Phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors
Author(s): Doi et al.
Tumor type(s): Solid tumors
Compound/Target: B7-H6/CD3 TcE
DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small ce
Author(s): Peters et al.
Tumor type(s): SCLC
Compound/Target: DLL3/TcE
A Phase III trial of zongertinib (BI 1810631) compared with standard of care in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain mutations: Beamion LUNG-2
Author(s): Wu et al.
Tumor type(s): NSCLC
Compound/Target: HER2-TKI